Can a Triple-Drug combo wipe out Slow-Growing lymphomas?

This phase 2 trial is testing whether adding tafasitamab to the standard combination of lenalidomide and rituximab can improve complete responses in people with untreated follicular lymphoma or marginal zone lymphoma. Participants receive the three-drug regimen for about a year, and researchers will measure how many achieve a complete response at the end of treatment. The study enrolls adults who need treatment but have not yet received any systemic therapy for their lymphoma.